Sign in
CompletedNo phase

A Study to Determine Pharmacokinetic Changes of Ceftriaxone in Patients With Liver Cirrhosis

Key facts

Who runs it
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
20 people enrolled
Started
10 Jul 2023
Ended
1 Jan 2026
Type of study
Observational
Treatments tested
  • No intervention (observational study)
Record updated
8 January 2026

Who can take part

Age
18 years to 100 years
Sex
Women and men

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Age ≥18 years
  • Clinical, radiological and/or histological diagnosis of liver cirrhosis and portal hypertension
  • Presence of ascites
  • Receiving ceftriaxone in the context of prophylaxis or treatment of infection
  • Indication for diagnostic and/or therapeutic paracentesis
  • Providing oral informed consent

Who cannot take part

  • None

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The investigators designed an observational multicenter explorative in vivo study to investigate the changes in ceftriaxone pharmacokinetics in blood and ascites. The investigators will include a total of 20 patients with liver cirrhosis admitted to the ward of participating hospitals. Patients are eligible when receiving ceftriaxone and concomitantly receive paracentesis. The investigators will collect all available waste blood samples of each participant, starting from study entry up until 48 hours after the last dosing interval of ceftriaxone. The investigators will collect all available waste ascites samples of each participant up until 48 hours after the last dosing interval of ceftriaxone. Duration of the trial: The study duration is variable and depends on the duration of ceftriaxone treatment and duration of hospital admission, which both are determined by the treating physician and is not influenced by study participation. Patients will be eligible for study inclusion when patients received (a single dose of) ceftriaxone treatment and undergo paracentesis during ceftriaxone treatment. The study will end 48 hours after the last dosing interval of ceftriaxone or until hospital discharge, whichever comes first. Study timeline: The investigators expect to enrol 1-2 participants every month. The total enrolment time will thus be approximately 12 months.

The group in the trial

  • observational ceftriaxone

    Patiënts with liver cirrhosis receiving ceftriaxone treatment.

    Treatment: No intervention (observational study)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Observational Explorative Study to Determine Pharmacokinetic Changes of Ceftriaxone in Blood and Ascites in Patients Admitted With Decompensated Liver Cirrhosis With or Without Renal Impairment.
Record updated
8 January 2026